OR WAIT 15 SECS
Gencor Pacific has received a U.S. patent (US 10,576,118 B2) for its fenugreek extract, Testofen, which is standardized to a 50% minimum content of Fenuside.
Gencor Pacific (Irvine, CA) has received a U.S. patent (US 10,576,118 B2) for its fenugreek extract, Testofen, which is standardized to a 50% minimum content of Fenuside. The patent was granted for the improvement of sexual function, reducing further decline of sexual hormones, and improvement in sexual hormonal levels in healthy aging males.
“We have made a significant investment into the clinical validation of Testofen, and receiving this patent further progresses our commitment and intellectual property supporting this superior fenugreek extract,” said Chase Shryoc, vice president of sales of Gencor, in a press release. “Testofen is the perfect addition for product formulations designed to support healthy sexual function, and performance.”
A number of double-blind placebo-controlled clinical trials have demonstrated the efficacy and safety of Testofen. The most recently published trial found that supplementation with Testofen significantly reduced body fat, increased muscle mass, and increased testosterone levels.